“The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.”, J Immunol, vol. 188, no. 10, pp. 5166-76, 2012.
, “Testing versus Hochberg's Method for Strongly Controlling Family-Wide Type I Error When Making All Pairwise Comparisons of Means in the SCORE Study”, in Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale FL, 2008.
, “Testing and linkage to HIV care in China: a cluster-randomised trial.”, Lancet HIV, vol. 4, no. 12, pp. e555-e565, 2017.
, “Ten-year incidence rates of age-related cataract in the Age-Related Eye Disease Study (AREDS): AREDS report no. 33.”, Ophthalmic Epidemiol, vol. 20, no. 2, pp. 71-81, 2013.
, “Ten-year Incidence Rates of Age-Related Cataract in the Age-Related Eye Disease Study (AREDS). AREDS Report No. 33”, Ophthalmic Epidemiology, vol. 20, pp. 71-81, 2013.
, “Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36.”, JAMA Ophthalmol, vol. 132, no. 3, pp. 272-7, 2014.
, “Ten-Year Follow-up of Age-Related Macular Degeneration in the Age-Related Eye Disease Study: AREDS Report No. 36”, JAMA Ophthalmol, vol. 132, pp. 272-277, 2014.
, “Tenofovir is not associated with renal dysfunction following solid organ transplantation”, presented at the 2011, Philadelphia, PA, 2011.
, “Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS”, presented at the 05Nov2020, 2020.
“Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS”, Blood, vol. 136, no. Supplement 1, pp. 32-33, 2020.
, “Tangency Outcomes for Clinical Trials”, in Society for Clinical Trials 35th Annual Meeting, Philadelphia, PA, 2014.
, “Tacrolimus/Sirolimus vs. Tacrolimus/Methotrexate for GVHD Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of BMT CTN Trial 0402”, in 54th Annual ASH Meeting, Atlanta, GA, 2012.
, “Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.”, Blood, vol. 124, no. 8, pp. 1372-7, 2014.
, “Tacrolimus/Sirolimus vs Tacrolimus/Methotrexate as GVHD Prophylaxis After Matched, Related Donor Allogeneic HCT”, Blood, vol. 124, pp. 1372-1377, 2014.
, “Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.”, Am J Transplant, vol. 6, no. 6, pp. 1377-86, 2006.
, “Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1-Year Report”, Am J Transplant, vol. 6, pp. 1377-1386, 2006.
, , , “Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.”, Pediatr Transplant, vol. 7, no. 3, pp. 217-22, 2003.
, “Tacrolimus vs cyclosporine A as primary immunosuppression in pediatric renal transplantation: A NAPRTCS study”, Pediatric Transplantation, vol. 7, pp. 217-222, 2003.
, , “Tacrolimus ointment is effective for facial and intertriginous psoriasis.”, J Am Acad Dermatol, vol. 51, no. 5, pp. 723-30, 2004.
, “Tacrolimus Ointment is Effective for Facial and Intertriginous Psoriasis”, Journal of the American Academy of Dermatology, vol. 51, pp. 723-30, 2004.
, “Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.”, J Am Acad Dermatol, vol. 48, no. 4, pp. 564-8, 2003.
, “Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas”, J Amer Acad Dermatology, vol. 48, pp. 564-8, 2003.
,